Categories Earnings, Health Care

Achieve Life Sciences (ACHV): Q4 2019 Earnings Snapshot

— Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a loss of $3.6 million, or $0.55 per share, last year.   

— Total operating expenses were $3.2 million.

— At December 31, 2019, cash, cash equivalents and restricted cash was $16.7 million.

— Achieve Life Sciences completed a meeting with the US FDA to finalize the Phase 3 cytisinicline clinical development program.  

— The company established an agreement with the FreeMind Group to assist in securing non-dilutive funding to evaluate cytisinicline in vapers and e-cigarette users.  

— The company closed an underwritten public offering for gross proceeds of $13.8 million, before underwriting discounts and commissions and offering expenses.  

— ACHV shares were up 12.7% in premarket hours on Friday.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top